59.28 USD
↘ 1.06 (1.76%)AT CLOSE (11:59 AM EDT)
Tarsus Pharmaceuticals, Inc. Common Stock
TARSNASDAQ • USD
58.51
↘ 0.78 (1.31%)
POST MARKET (AS OF 05:01 PM EDT)
Post Market
AS OF 05:01 PM EDT
58.51
↘ 0.78 (1.31%)
Market: CLOSED
Open?$60.86
High?$62.50
Low?$58.80
Prev. Close?$60.34
Volume?370.1K
Avg. Volume?751.0K
VWAP?$59.84
Rel. Volume?0.49x
Bid / Ask
Bid?$50.74 × 100
Ask?$68.07 × 100
Spread?$17.33
Midpoint?$59.41
Valuation & Ratios
Market Cap?2.6B
Shares Out?43.0M
Float?36.7M
Float %?86.2%
P/E Ratio?N/A
P/B Ratio?7.31
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) trades at $59.28 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place TARS at a fair price relative to peers.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Market Cap
2.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2020-10-16
Address
15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
Phone: (949) 409-9820
IRVINE, CA 92618
Phone: (949) 409-9820
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?100
Momentum?97
Short Sent.?40
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.99Safe
Confidence?63%Moderate
Short InterestHigh
Short % of Float?13.38%High
Short Interest?4.9M
Days to Cover?5.7
Free Float36.7M
Avg Daily Volume855.8K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.74Strong
Quick Ratio?3.71Strong
Cash Ratio?0.71Adequate
Debt/Equity?0.21Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?7.31FAIR▾
Peers100
S&P26
P/S?4.77FAIR▾
Peers100
S&P31
P/FCF?N/A▾
EV/EBITDA?-45.5CHEAP▾
S&P97
EV/Sales?4.71FAIR▾
Peers100
S&P38
Returns & Efficiency
ROE?-14.0%WEAK▾
S&P9
ROA?-8.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-31539000
Enterprise Value?$2.5B
Fundamentals ratios updated end of day